Loading clinical trials...
Loading clinical trials...
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBF 1120 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Conditions
Interventions
BI 6727
BIBF 1120
Locations
2
Italy
1230.7.39002 Boehringer Ingelheim Investigational Site
Ancona, Italy
1230.7.39001 Boehringer Ingelheim Investigational Site
Milan, Italy
Start Date
December 1, 2009
Primary Completion Date
February 1, 2013
Completion Date
February 1, 2013
Last Updated
July 30, 2018
NCT07213804
NCT00026884
NCT07159659
NCT07169851
NCT07191730
NCT06662786
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions